NJ jury slaps Roche with $1.5M Accutane verdict; Ex-Actelion execs joins Novimmune as CFO;

@FiercePharma: Novartis and Roche now have France eyeing competition issues. Story | Follow @FiercePharma

@TracyStaton: RT from BioPharmaJosh: WSJ looks at how JNJ beat out NVS & CELG for Imbruvica. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: With hemophilia drugs in the pipeline, Bayer Healthcare will invest €500 M in new production in Germany. Release | Follow @EricPFierce

@CarlyHFierce: From FP Marketing: Hearts, stars, diamonds: Pharma could turn pill shapes into lucky charms. More | Follow @CarlyHFierce

> A New Jersey jury ordered Roche ($RHHBY) to pay $1.5 million in damages to a woman who developed bowel disease after using its Accutane acne medicine. Report

> Novimmune snapped up former Actelion ($ATLN) CFO Andrew J. Oakley to be its new CFO. Report

> Another Indian drug supplier, Canton Laboratories, was slapped with an FDA warning letter for manufacturing shortfalls. Report

> The U.K.'s National Health Service will hike its prescription fees by 40% over the next two years. Report

> Consumer Reports says that acid-reducing drugs like AstraZeneca's ($AZN) Nexium are overused. Report

Medical Device News

@FierceMedDev: Would you wear this first-of-its kind migraine prevention device if it worked? Story | Follow @FierceMedDev

@MarkHFierce: This week's FierceDiagnostics has news on Alzheimer's biomarkers, GE and more. Newsletter | Follow @MarkHFierce

@MichaelGFierce: Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: PowerVision implanted its fluid intraocular lenses into 10 patients as part of a new clinical study. Article | Follow @EmilyWFierce

@GalenMoore: A cash-strapped SF biotech's ovarian cancer drug may actually get to Phase III. Story | Follow @GalenMoore

> Fresenius Medical Care to pour $140M into Tennessee manufacturing expansion. More

> Myriad can't stop Ambry Genetics from selling its breast cancer test--for now. Story

> J&J's $2.5B-plus metal hip settlement offer approaches April 1 deadline. Article

Biotech News

@FierceBiotech: German billionaire pair backs $76M gamble on Glycotope's cancer and fertility drug trials. Article | Follow @FierceBiotech

@JohnCFierce: Purdue preps potential Zohydro killer for FDA review after positive PhIII. News | Follow @JohnCFierce

@DamianFierce: Farewell to dear old Alderley as AstraZeneca finds a buyer for its R&D HQ. Story | Follow @DamianFierce

@EmilyMFierce: FDA approval of Cefaly migraine device is encouraging since triptans used to treat migraines come with risk of rebound headaches. | Follow @EmilyMFierce

> Oxigene roars back to life on positive ovarian cancer study. More

> Geron shares blasted as FDA slams the brakes on imetelstat studies. Piece

Drug Delivery News

> Mallinckrodt's U.S. pain drug approval brings Depomed a $10M delivery tech milestone. More

> NeuroDerm preps for Parkinson's patch PhII trial. Story

> Delivery method uses a cancer cell's power source to trigger drug release. Article

> Study: Drug-delivering ring halts HIV, herpes, pregnancy for months at a time. News

> Caisson expands Novo partnership with $167M insulin-delivery deal. Report

> Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item

Diagnostics News

> 3 Alzheimer's biomarkers build over time but decline after symptoms appear. Story

> Restless legs syndrome mulled as a diagnostic biomarker for multiple conditions. Article

> Boston Heart launches a new inflammation test for cardiovascular disease. Story

> Quest Diagnostics boosts 2014 guidance after closing $570M Solstas acquisition. News

> GE Healthcare prostate cancer imaging agent spurs the formation of a U.K. Dx startup. Story

> Debiopharm invests $6M into Immunexpress for sepsis test development. Brief

Pharma Marketing News

> Big Data's double-edged sword: Better drug marketing, bigger SG&A cost cuts. Story

> GlaxoSmithKline gets judge's say-so for false-advertising suit against Teva. News

> Can rival allergy-drug launches deliver for both Stallergenes and Merck? Story

> Online coupon bank maps a new marketing route into physicians' offices. Story

> Hearts, stars, diamonds: Pharma could turn pill shapes into Lucky Charms. Article

> German med schools perfectly OK with pharma-rep visits and gifts. Brief

And Finally... The number of young American adults taking ADHD meds nearly doubled from 2008 to 2012. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.